Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gerresheimer AGGRRMF +2.83%58 Net-Net Working Capital is $-92.01 as of Nov. 2025. GuruFocus rates GRRMF with a GF Score™ of 58/100 and a GF Value™ of $191.08 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 420 Medical Devices & Instruments companies, Gerresheimer AG ranks worse than 238095% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Gerresheimer AG's Net-Net Working Capital for the quarter that ended in Nov. 2025 was $-92.01.
The industry rank for Gerresheimer AG's Net-Net Working Capital or its related term are showing as below:
GRRMF's Price-to-Net-Net-Working-Capital is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 6.655 * Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.
Gerresheimer AG (OTCPK:GRRMF) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Gerresheimer AG Net-Net Working Capital Related Terms
Gerresheimer AG Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Gerresheimer AG's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRRMF vs ISRG, BDX, MDLN: Net-Net Working Capital Comparison
For the Medical Instruments & Supplies subindustry, Gerresheimer AG's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gerresheimer AG Price-to-Net-Net-Working-Capital vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gerresheimer AG's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Gerresheimer AG's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $-92.01 mean?
Gerresheimer AG (GRRMF) has a Net-Net Working Capital of $-92.01 as of Nov. 2025. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Gerresheimer AG According to the industry distribution chart, Gerresheimer AG ranks #999999 out of 420 companies in the Medical Devices & Instruments industry.
Is Gerresheimer AG's Net-Net Working Capital too high?
Gerresheimer AG's current Net-Net Working Capital is $-92.01. Based on the distribution chart, Gerresheimer AG ranks #999999 out of 420 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Gerresheimer AG has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gerresheimer AG's Net-Net Working Capital compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Gerresheimer AG ranks #999999 out of 420 companies for Net-Net Working Capital. This places Gerresheimer AG in the lower half of its industry. The industry median Net-Net Working Capital is 6.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Medical Devices & Instruments company?
The median Net-Net Working Capital among Medical Devices & Instruments companies is 6.66, based on 420 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Gerresheimer AG For the Medical Devices & Instruments industry, the median Net-Net Working Capital is 6.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gerresheimer AG's current Net-Net Working Capital is $-92.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gerresheimer AG stock overvalued right now?
Based on GuruFocus' analysis, Gerresheimer AG (GRRMF) is currently considered Possible Value Trap. The stock's GF Value™ is $191.08, compared to a current price of $31.68 — trading 83.4% below its estimated fair value. The current Net-Net Working Capital is $-92.01. Gerresheimer AG's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Gerresheimer AG (GRRMF), the current Net-Net Working Capital is $-92.01 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gerresheimer AG (GRRMF) Overvalued in 2026?
Based on GuruFocus' analysis, Gerresheimer AG stock appears to be undervalued.
The current stock price of $31.68 is trading 83.4% below its estimated GF Value™ of $191.08.
GuruFocus considers Gerresheimer AG to be Possible Value Trap.
Key valuation signals for GRRMF:
Net-Net Working Capital: $-92.01
GF Value™: $191.08 vs. price of $31.68 (83.4% below fair value)
No single metric tells the full story. See the GRRMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gerresheimer AG provides medicine packaging, drug delivery devices, and solutions with a product range for pharma, health, well-being, and biotech. The firm operates in three segments: The plastics and devices segment consists of products for simple and safe drug delivery along with packaging for liquid and solid medicines, The primary packaging glass segment produces glass packaging products for the pharma and cosmetics industries also for food and beverage industry and The advanced technologies segment works on technical and digital solutions to improve the therapy outcome for patients. The company generates the majority of its revenue in Europe, with sales in Germany contributing the major proportion of any country.
58GF Score
Get the complete analysis for GRRMF
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRRMF has been successfully added to your 
